Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Return on Capital Employed (2021 - 2025)

Lyra Therapeutics has reported Return on Capital Employed over the past 5 years, most recently at 1.02% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 1.02% for Q4 2025, up 59.0% from a year ago — trailing twelve months through Dec 2025 was 1.02% (up 59.0% YoY), and the annual figure for FY2025 was 0.74%, up 31.0%.
  • Return on Capital Employed for Q4 2025 was 1.02% at Lyra Therapeutics, down from 0.91% in the prior quarter.
  • Over the last five years, Return on Capital Employed for LYRA hit a ceiling of 0.49% in Q3 2022 and a floor of 1.64% in Q1 2025.
  • Median Return on Capital Employed over the past 5 years was 0.91% (2025), compared with a mean of 0.95%.
  • Biggest five-year swings in Return on Capital Employed: surged 93bps in 2023 and later plummeted -104bps in 2025.
  • Lyra Therapeutics' Return on Capital Employed stood at 1.01% in 2021, then surged by 45bps to 0.56% in 2022, then decreased by -7bps to 0.6% in 2023, then plummeted by -168bps to 1.61% in 2024, then soared by 37bps to 1.02% in 2025.
  • The last three reported values for Return on Capital Employed were 1.02% (Q4 2025), 0.91% (Q3 2025), and 0.96% (Q2 2025) per Business Quant data.